Procyrion, Inc. Chosen to Present at the 2016 Device Therapies for Heart Failure in Paris


HOUSTON, TX (December 1st, 2016) – Heart pump developer, Procyrion, Inc. has been selected to participate in the 2016 Device Therapies for Heart Failure (D-HF), which will take place December 2 and 3 at the Novotel Paris Centre Tour Eiffel in Paris, France. COO Jace Heuring will deliver a presentation and discuss Aortix™, the first catheter-deployed circulatory assist device intended for long-term use in the treatment of chronic heart failure.

Procyrion’s winning technology, Aortix™, which is thinner than a #2 pencil, is the first catheter-based heart pump designed specifically for the ambulatory treatment of NYHA Class III-IVa heart failure patients who are too sick for medication alone, but not sick enough for risky surgical interventions (e.g. LVAD or transplant). The small but powerful micro pump is placed downstream of the heart in a simple cath-lab procedure and works to support heart function by accelerating native blood flow.

Heart failure is the next frontier in cardiovascular interventions. D-HF will be an interactive workshop including lectures given by leading experts in the field, recorded cases and debates focused on the development of ventricle restoration strategies, device based strategies to improve cardiac output and new percutaneous monitoring systems.

“Millions are affected by heart failure and medical device innovation faces continued pressure not only to improve patient quality of life, but also to reduce the cost of care,” stated Jace Heuring, COO Procyrion, Inc. “Presenting at D-HF gives us the opportunity to demonstrate exactly how Aortix can do just that.”

Heuring’s presentation will take place Saturday, December 3rd during the Intermediate and Chronic Support for Ambulatory Heart Failure session at 3:30 - 5:45 PM local time.


Houston-based medical device firm Procyrion, Inc. is developing the first catheter-deployed, intra-aortic pump for ambulatory use.  The device is designed to rest and heal the heart by reducing afterload while simultaneously improving blood flow to vital organs. This groundbreaking cardiology tool, conceived by cardiologist Dr. Reynolds M. Delgado, III, medical director of Mechanical Support Devices in Heart Failure at the Texas Heart Institute, is expected to provide a minimally invasive treatment option for millions of chronic heart failure patients.  For more information, visit or call 713.579.9227.

Dana Summers
Penman PR

Read More